Abbott Laboratories (ABT) 10-K Summary — Year Ended Dec 31, 2023
Abbott Laboratories filed its annual report covering the business overview, risk factors, and financial results. The company reported a decline in revenue compared to the prior year.
Key takeaway
Year ended Dec 31, 2023 · FY2025 10-K
Abbott Laboratories filed its annual report covering the business overview, risk factors, and financial results. The company reported a decline in revenue compared to the prior year.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$40.1B
Revenue reported for the fiscal year.
Operating income
$6.5B
Income from operations reported for the year.
Net income
$5.7B
Net income reported for the year.
Operating cash flow
$7.3B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $43.1B | n/a |
| Dec 31, 2022 | $43.7B | +1.3% |
| Dec 31, 2023 | $40.1B | -8.1% |
Business overview
Abbott Laboratories operates in the healthcare sector, including diagnostics, medical devices, nutrition, and pharmaceuticals. The Business overview section describes its operations and segments.
Financial performance
Annual revenue decreased from the prior year, following a rise in the previous period. The company reported operating income, net income, and positive operating cash flow.
Material risks
The Risk Factors section identifies potential adverse effects from regulatory, competitive, and economic conditions. The company cautions that these factors could materially affect its results.
Liquidity and capital
The company generated positive operating cash flow and net income, supporting its liquidity. Capital allocation themes are discussed in the Management Discussion and Analysis.
What to watch
Monitor the company's revenue trend in the next filing to see if the decline reverses.